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Prediction of mortality in adult patients 
with sepsis using six biomarkers: a systematic 
review and meta-analysis
Andreas Pregernig1, Mattia Müller1, Ulrike Held2 and Beatrice Beck‑Schimmer1* 
Abstract 
Background: Angiopoietin‑1 (Ang‑1) and 2 (Ang‑2), high mobility group box 1 (HMGB1), soluble receptor for 
advanced glycation endproducts (sRAGE), soluble triggering receptor expressed on myeloid cells 1 (sTREM1), and 
soluble urokinase‑type plasminogen activator receptor (suPAR) have shown promising results for predicting all‑cause 
mortality in critical care patients. The aim of our systematic review and meta‑analysis was to assess the prognostic 
value of these biomarkers for mortality in adult patients with sepsis.
Methods: A systematic literature search of the MEDLINE, PubMed, EMBASE, and Cochrane Library databases, for 
articles in English published from 01.01.1990 onwards, was conducted. The systematic review focused exclusively on 
observational studies of adult patients with sepsis, any randomized trials were excluded. For the meta‑analysis, only 
studies which provide biomarker concentrations within 24 h of admission in sepsis survivors and nonsurvivors were 
included. Results are presented as pooled mean differences (MD) between nonsurvivors and survivors with 95% 
confidence interval for each of the six biomarkers. Studies not included in the quantitative analysis were narratively 
summarized. The risk of bias was assessed in all included studies using the Quality in Prognosis Studies (QUIPS) tool.
Results: The systematic literature search retrieved 2285 articles. In total, we included 44 studies in the qualitative 
analysis, of which 28 were included in the meta‑analysis. The pooled mean differences in biomarker concentration 
(nonsurvivors − survivors), measured at onset of sepsis, are listed as follows: (1) Ang‑1: − 2.9 ng/ml (95% CI − 4.1 to 
− 1.7, p < 0.01); (2) Ang‑2: 4.9 ng/ml (95% CI 2.6 to 7.1, p < 0.01); (3) HMGB1: 1.2 ng/ml (95% CI 0.0 to 2.4, p = 0.05); (4) 
sRAGE: 1003 pg/ml (95% CI 628 to 1377, p < 0.01); (5) sTREM‑1: 87 pg/ml (95% CI 2 to 171, p = 0.04); (6) suPAR: 5.2 ng/
ml (95% CI 4.5 to 6.0, p < 0.01).
Conclusions: Ang‑1, Ang‑2, and suPAR provide beneficial prognostic information about mortality in adult patients 
with sepsis. The further development of standardized assays and the assessment of their performance when included 
in panels with other biomarkers may be recommended.
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Background
The burden of sepsis stays considerably high to this day 
[1]. Estimates suggest it affects millions of people world-
wide and annually causes nearly 6 million deaths [2]. Due 
to its aggressive course, it requires rapid recognition and 
urgent treatment. One challenge remains to accurately 
identify patients with a higher risk of mortality, and who 
might benefit from additional monitoring or treatment 
measures. As sepsis is a highly intricate condition and its 
clinical assessment is often difficult, the additional use of 
biomarkers to help pinpoint such patients is an attractive 
solution. But the heterogeneity and complex pathophysi-
ology of sepsis entail that single biomarkers often provide 
imprecise information, and biomarkers which reliably 
qualify as predictors of outcome in sepsis patients remain 
scarce [3–5].
Recent years have seen the emergence of promising 
biomarkers. These include angiopoietin 1 (Ang-1) and 
2 (Ang-2), high mobility group box 1 protein (HMGB1), 
soluble receptor for advanced glycation endproducts 
(sRAGE), soluble triggering receptor expressed on 
myeloid cells 1 (sTREM1), and soluble urokinase-type 
plasminogen activator receptor (suPAR). Other prom-
ising biomarkers exist, but they do not predict the out-
come of sepsis. Moreover, analysis of some biomarkers 
is extremely complex, which could hamper their future 
implementation into a clinical setting.
Angiopoietins 1 and 2 are glycoproteins which act on 
angiogenesis and have a direct, but opposing, effect on 
blood vessels. Ang-1 supports stabilization, survival and 
development of endothelial cells, and has anti-inflamma-
tory properties while Ang-2 is proinflammatory, induces 
endothelial cell destabilization and vascular leakage, and 
promotes cell death [6]. Therefore, for prediction pur-
poses, both proteins have to be evaluated at the same 
time.
HMGB1 is a nuclear protein with proinflammatory fea-
tures when released by dying cells or secreted by immune 
and inflammatory cells such as neutrophils, monocytes 
and macrophages in response to infectious or non-infec-
tious stimuli [7].
The cell-surface receptors RAGE, TREM-1, and uPAR 
are found and measured in the blood as their soluble 
form: sRAGE, sTREM-1, and suPAR, respectively. RAGE 
is a cell-surface receptor of the immunoglobulin super-
family, primarily expressed in the lung. When stimu-
lated, RAGE leads to cell activation and the initiation and 
propagation of an inflammatory response [8]. TREM-1 
is found on neutrophils and monocytes. Infection stim-
ulates the expression of the receptor, and its activa-
tion leads to a heightened production of inflammatory 
cytokines [9, 10]. Finally, uPAR is present on immune 
cells including monocytes and T-lymphocytes, as well 
as non-immune cells such as endothelial cells and fibro-
blasts. This marker is notably implicated in cell adhesion, 
chemotaxis, immune activation and cellular signaling 
[11].
Clinical studies evaluating the performance of these 
biomarkers to predict mortality in critically ill patients 
have shown relevant findings [12, 13]. Some have been 
reviewed by combining evidence from cohorts of patients 
with trauma, sterile inflammation or bacteremia in addi-
tion to patients with overt sepsis or septic shock [14–17]. 
Confirming the prognostic value of any of these six bio-
markers in patients with sepsis could lead to more effi-
cient surveillance or triage in the intensive care unit 
(ICU) aiming to reduce mortality.
The aim of our systematic review and meta-analysis is 
therefore to assess the prognostic value at onset of sepsis 
of serum Ang-1, Ang-2, HMGB1, sRAGE, sTREM-1, and 
suPAR, in adult patients with sepsis or septic shock.
Methods
This study was conducted following the Preferred 
Reporting Items for Systematic Reviews and Meta-analy-
ses (PRISMA) guidelines [18]. It was recorded on PROS-
PERO, the prospective register of systematic reviews, 
under the registration ID: CRD42018081226.
Search strategy
An information specialist conducted a systematic lit-
erature search of the MEDLINE, PubMed, EMBASE, 
and Cochrane Library databases, for articles in English, 
published from 01.01.1990 onwards and conducted on 
humans. The full search strategy is detailed in the Addi-
tional file 1. We additionally screened the reference lists 
of selected studies and of related systematic reviews, to 
identify any relevant studies not found by the electronic 
search.
Study selection
Studies were first screened by title and/or by abstract. For 
studies included after title/abstract screening, full texts 
were obtained for formal inclusion or exclusion into our 
study. Studies were selected independently by two review 
authors (AP, MM). Discrepancies were resolved by con-
sensus or by arbitration with a third author if necessary 
(BBS).
Inclusion and exclusion criteria
This study includes only observational studies which 
provide prognostic information on one of the biomark-
ers in adult (≥ 16 years) patients with sepsis, and which 
applied either the sepsis-1, sepsis-2, and/or sepsis-3 
definitions [19]. Prognostic information was defined as 
all-cause mortality, at any timepoint. Reviews, letters, 
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commentaries, correspondences, case reports, confer-
ence abstracts, expert opinions, editorials, in  vitro and 
animal experiments and interventional studies (rand-
omized or non-randomized) were excluded to allow eval-
uation of similarly retrieved data.
In case of publications with overlapping cohorts or 
duplicate data, only the publication with the highest 
number of patients was included.
Data extraction and analysis
The following data were extracted from published arti-
cles and supplementary material if available: (i) general 
study information: author, year, country, study design 
(prospective or retrospective), clinical setting; (ii) patient 
characteristics: sample size, age, male proportion, sever-
ity of sepsis, sepsis definition used; (iii) biomarker 
measurement: time point of measurement, assay; (iv) 
mortality: follow-up duration, rate of mortality (v) out-
come measures: biomarker concentration in survivors 
and nonsurvivors, area under the receiver operating 
characteristic (ROC) curve for prediction of mortality 
with cut-off point, sensitivity, specificity, positive predic-
tive value, negative predictive value, positive likelihood 
ratio, and negative likelihood ratio.
The data were recorded independently and in dupli-
cate by two review authors (AP, MM) on separate cop-
ies of an excel spreadsheet. These were compared, and 
any discrepancies were resolved by consensus. Data not 
directly available in published articles was provided by 
some study authors directly, or calculated based on data-
sets provided by authors.
Quality assessment was conducted using the Qual-
ity in Prognosis Studies (QUIPS) tool [20]. Each study 
was assessed for risk of bias through six domains: study 
participation, study attrition, prognostic factor measure-
ment, confounding measurement and account, outcome 
measurement, analysis and reporting. For each domain, 
two review authors (AP, MM) independently assigned a 
rating of low, moderate, or high risk of bias. Again, dis-
crepancies were resolved through discussion.
To assess the prognostic value of the biomarkers for 
mortality, a meta-analysis of differences in biomarker 
levels between nonsurvivors and survivors of sepsis was 
performed, and the results of ROC analyses within stud-
ies for prediction of mortality according to biomarker 
levels were narratively summarized.
The meta-analysis includes studies which provide bio-
marker concentrations at baseline (within 24 h of admis-
sion) in sepsis survivors and nonsurvivors. Studies which 
did not provide biomarker concentrations at baseline 
(within 24  h of admission) in sepsis survivors and non-
survivors were not included in the quantitative analysis, 
and were narratively summarized.
For pooling of the results, reported means with stand-
ard deviations (SD) were used for calculations. If studies 
reported means with standard errors (SE), the SD was 
computed using the formula provided by the Cochrane 
Collaboration: SD = SE * √N [21]. For studies which 
reported biomarker concentrations as median and range 
or interquartile range (IQR), we estimated the mean and 
SD according to the formulas by Wan et al. [22]. To con-
firm the reliability of these estimations, we performed 
them in duplicate using the formulas by Luo et  al. [23], 
and conducted a sensitivity analysis to compare the 
results of the two methods. Both methods have shown 
good reliability for these estimations, even in presence of 
deviation from the normal distribution [24].
Results are presented as forest plots of pooled mean 
differences (MD) between nonsurvivors and survivors 
with 95% confidence interval, separately for each of the 
six biomarkers. Statistical significance was defined at the 
5% level (p < 0.05). Heterogeneity was measured using 
among-study variance (τ2), the χ2 test, and the I2 statis-
tic. For biomarkers with an I2 < 50%, results were pooled 
using a fixed effects model, otherwise a random effects 
model was used. All statistical analyses were performed 
using R (version 3.4.3) [25], and using the dplyr [26], 
ggplot2 [27], and meta [28] packages.
Results
Study selection and characteristics
The systematic literature search retrieved 2285 articles 
(Fig. 1). After initial screening by title and/or by abstract, 
2171 articles were excluded. The full texts of the remain-
ing 114 articles were examined, and 70 studies were 
further excluded. A list of the excluded articles with rea-
sons is available (Additional file 2). In total, we included 
44 studies in the qualitative analysis, of which 28 were 
included in the meta-analysis. All studies included in the 
qualitative analysis were published between 2005 and 
2017. Forty-one of the 44 studies followed a prospective 
design, whereas 3 were retrospective. All of the included 
studies sampled blood at admission or enrollment in the 
study for biomarker determination. The biomarkers were 
widely measured using commercials assays, but in 2 stud-
ies (both for HMGB1) non-commercial methods were 
used for the measurements.
The main outcome was either 28-day mortality, 30-day 
mortality, ICU mortality, in hospital mortality, or 90-day 
mortality. Details regarding the study design and popu-
lation, assay used, and mortality follow-up of included 
studies are presented in Table 1.
Angiopoietin 1 and 2
Ten of the 44 included studies involve Ang-1 and Ang-2 
[29–38]. The number of patients across these studies 
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ranged from 20 to 943, and the mean or median age of 
the patients from 51 to 75 years.
For the meta-analysis, 2 studies had suitable data for 
Ang-1 and 7 studies for Ang-2. There is strong evidence 
that both Ang-1 and Ang-2 measured at onset of sepsis dif-
fer between nonsurvivors and survivors. Ang-1, the only 
anti-inflammatory biomarker included in this review, was 
lower in nonsurvivors than in survivors, with a pooled 
mean difference of − 2.9  ng/ml (95% CI − 4.1 to − 1.7; 
p < 0.01). On the contrary, Ang-2 was higher in nonsur-
vivors than in survivors. The pooled mean difference for 
Ang-2 is 4.9 ng/ml (95% CI 2.6 to 7.1; p < 0.01). All results of 
the meta-analysis are presented in the forest plots of Fig. 2.
Heterogeneity between studies was not considered 
substantial in the analyses of Ang-1 and Ang-2, with 
 I2 values of 0% for Ang-1 (p = 0.58) and 48% for Ang-2 
(p = 0.07). Therefore, a fixed effects model was used for 
the analyses.
To further determine the prognostic value of the bio-
markers, results of receiver operating characteristic 
(ROC) analyses for prediction of mortality according to 
day 1 biomarker concentrations were summarized. Six of 
the 10 studies reported data for ROC analyses of Ang-1 
and/or Ang-2. The area under the curve (AUC) ranged 
from 0.620 to 0.778 for Ang-1 and 0.632 to 0.960 for Ang-
2. The results with details regarding optimal cutoff points 
and sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), positive likelihood ratio 
(LR+) and negative likelihood ratio (NPV) are presented 
in Table 2.
One study [33] did not report biomarker concentra-
tions or ROC analyses, but still contains prognostic 
information. This study included patients with systemic 
inflammatory response syndrome (SIRS), a subset of 
whom had sepsis. The authors retrospectively performed 
a multivariate analysis of biomarker association with 
Fig. 1 PRISMA flow diagram of study selection
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Table 1 Characteristics of all included studies
Author Year Country Study design N Assay Outcome
Angiopoietin 1 and 2
 Parikh [35] 2006 USA Prospective 22 ELISA (R&D Systems) Hospital mortality
 Kranidioti [31] 2009 Greece Prospective 90 ELISA (R&D Systems) 28‑day mortality
 Siner [37] 2009 USA Prospective 66 ELISA (R&D Systems) 28‑day, ICU, and hospital mortality
 van der Heijden [38] 2009 Netherlands Prospective 50 ELISA (R&D Systems) 28‑day, ICU, and hospital mortality
 Davis [29] 2010 Australia Prospective 124 ELISA (R&D Systems) 28‑day mortality
 Ricciuto [36] 2011 Canada Retrospective 70 ELISA (R&D Systems) 28‑day mortality
 Fang [30] 2015 China Prospective 495 ELISA (Abcam) 28‑day mortality
 Lin [32] 2015 Taiwan Prospective 96 ELISA (Sekisui Diagnostics) Hospital mortality
 Mikacenic [33] 2015 USA Retrospective 943 Multiplex immunoassay (Meso 
Scale Discovery)
28‑day mortality
 Palud [34] 2015 France Prospective 20 ELISA (RayBiotech) 7‑day, 10‑day, and 28‑day mortality
Total number of patients = 1976
HMGB1
 Sunden‑Cullberg [39] 2005 Sweden Prospective 64 Western immunoblotting (Cocalico 
Biologicals)
28‑day mortality
 Gibot [40] 2007 France Prospective 42 ELISA (Shino‑Test Corporation, 
customized)
28‑day mortality
 van Zoelen [41] 2007 Belgium Prospective 111 ELISA (non‑commercial) Hospital mortality
 Karlsson [42] 2008 Finland Prospective 257 ELISA (Shino‑Test Corporation) ICU and hospital mortality
 Huang [43] 2011 China Prospective 131 ELISA (Shino‑Test Corporation) Not specified
 Ueno [44] 2011 Japan Prospective 60 ELISA (non‑commercial) Not specified
 Narvaez‑Rivera [45] 2012 Mexico Prospective 30 ELISA (IBL International) 28‑day mortality
 Charoensup [46] 2014 Thailand Prospective 77 ELISA (IBL International) 1‑month mortality
 Ravetti [47] 2015 Brazil Prospective 75 ELISA (IBL International) 28‑day and ICU mortality
 Lee [48] 2016 Korea Prospective 212 ELISA (IBL International) 28‑day, ICU, and Hospital mortality
 Nobre [49] 2016 Brazil Prospective 62 ELISA (IBL International) 28‑day and ICU mortality
Total number of patients = 1121
sRAGE
 Bopp [50] 2008 Germany Prospective 37 ELISA (R&D Systems) 28‑day mortality
 Narvaez‑Rivera [45] 2012 Mexico Prospective 30 ELISA (R&D Systems) 28‑day mortality
 Brodska [51] 2013 Czech Republic Prospective 54 ELISA (R&D Systems) 28‑day mortality
 Hamasaki [52] 2014 Brazil Prospective 73 Multiplex immunoassay (EMD 
Millipore)
Not specified
Total number of patients = 194
sTREM‑1
 Gibot [53] 2005 France Prospective 63 Immunoblotting (R&D Systems) 28‑day mortality
 Giamarellos‑Bourboulis [54] 2006 Greece Prospective 90 ELISA (R&D Systems, customized) 28‑day mortality
 Phua [55] 2008 Singapore Prospective 93 Immunoblotting (R&D Systems) 28‑day mortality
 Suarez‑Santamaria [56] 2010 Spain Prospective 253 ELISA (R&D Systems, customized) 7‑day, 28‑day, hospital, 6‑months, 
and 1‑year mortality
 Zhang [57] 2011 China Prospective 52 ELISA (R&D Systems) 28‑day mortality
 Su [58] 2012 China Prospective 160 ELISA (R&D Systems) 28‑day mortality
 Li [59] 2014 China Prospective 102 ELISA (R&D Systems) 28‑day mortality
 Bayram [60] 2015 Turkey Prospective 74 ELISA (R&D Systems) Not specified
 Ravetti [47] 2015 Brazil Prospective 75 ELISA (R&D Systems) 28‑day and ICU mortality
 Charles [61] 2016 France Prospective 190 ELISA (R&D Systems) 14‑day and ICU mortality
 Brenner [62] 2017 Germany Retrospective 120 ELISA (R&D Systems) 90‑day mortality
Total number of patients = 1272
suPAR
 Giamarellos‑Bourboulis [63] 2012 Greece Prospective 1914 ELISA (ViroGates) 28‑day mortality
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28-day mortality in the sepsis patients. After adjust-
ment for various variables (including age, gender and 
comorbidities), they report odds ratios (OR) for mortal-
ity at 28 days of 0.69 (95% CI 0.59 to 0.81; p = 2.9 × 10−6) 
per doubling of Ang-1 and 1.79 (95% CI 1.43 to 2.24; 
p = 2.9 × 10−6) per doubling of Ang-2.
HMGB1
Out of 44 included studies 11 discuss HMGB1 [39–49]. 
The sample size of the studies varied between 30 and 257 
patients. The patients were aged 34 (mean or median) 
to 68  years. The reason for the low age of patients, is 
because the study by Huang et al. [43] included patients 
with sepsis in burn patients.
Eight of those studies had suitable data for the meta-
analysis. HMGB1 measured at onset of sepsis is the only 
biomarker that did not differ between nonsurvivors and 
survivors of sepsis, with a pooled mean difference of 
1.2 ng/ml (95% CI 0.0 to 2.4; p = 0.05) (Fig. 2).
There was no significant heterogeneity between studies 
for HMGB1 (I2 = 0%; p = 0.89), so a fixed effects model 
was used for the pooling of the results.
Only 2 of the 11 studies contained ROC analyses, with 
AUCs of 0.570 and 0.610, respectively (Table 2).
In addition, 3 studies did not report sufficient data to 
be included in the meta-analysis and did not perform 
ROC analyses [39, 43, 46].
Sunden-Cullberg et al. studied the kinetics of HMGB1 
in sepsis patients. They measured HMGB1 in sepsis non-
survivors and survivors using two different (non-com-
mercial) methods. They report conflicting results, one 
method showing lower HMGB1 levels in nonsurvivors 
than in survivors, the other method showing no differ-
ence between the two groups.
The study by Huang et  al. includes burn patients, 
some of which developed sepsis. In this subgroup of 
sepsis patients, they reported no significant difference in 
HMGB1 concentrations on postburn day 1 between non-
survivors and survivors.
Charoensup et al. studied a specific cohort of patients 
with sepsis due to Burkholderia pseudomallei, and they 
report that nonsurvivors had higher HMGB1 levels than 
survivors at the time of diagnosis.
sRAGE
For sRAGE only 4 studies could be included [45, 50–52]. 
The sample size of these studies ranged from 30 to 73 
patients. The patients had a mean or median age of 38 to 
64 years.
Three of the 4 studies were suitable for the meta-anal-
ysis. Our results show strong evidence that sRAGE is 
higher in nonsurvivors than survivors. The pooled mean 
difference for sRAGE is 1003 pg/ml (95% CI 628 to 1377; 
p < 0.01) (Fig. 2).
There was no substantial heterogeneity between stud-
ies, with an I2 value of 0% (p = 0.96), so we used a fixed 
effects model for pooling.
Two of the studies had data regarding ROC analyses. 
While optimal cutoff points are summarized for both 
studies, only one reported an AUC with a value of 0.660 
(Table 2).
One study [52] could not be included in the meta-
analysis and did not report ROC analysis. Hamasaki et al. 
indicate that increased levels of sRAGE in septic shock 
patients are associated with mortality.
sTREM‑1
Eleven of the 44 included studies involve sTREM-1 
[47, 53–62]. The sample size of patients in the differ-
ent studies ranged from 52 to 253 patients. A mean or 
median age of 53 years to 70 years was identified.
Six of these studies were suitable for meta-analysis. 
sTREM-1 was significantly higher in nonsurvivors, 
ELISA enzyme-linked immunosorbent assay, ICU intensive care unit
Table 1 (continued)
Author Year Country Study design N Assay Outcome
 Gustafsson [64] 2012 Sweden Prospective 49 ELISA (ViroGates) 90‑day mortality
 Hoenigl [65] 2013 Austria Prospective 132 ELISA (ViroGates) 28‑day mortality
 Suberviola [66] 2013 Spain Prospective 137 ELISA (ViroGates) ICU and hospital mortality
 Donadello [67] 2014 Belgium Prospective 258 ELISA (ViroGates) 28‑day and ICU mortality
 Khater [68] 2016 Egypt Prospective 80 ELISA (R&D Systems) 30‑day mortality
 Liu [69] 2016 China Prospective 137 ELISA (ViroGates) 28‑day mortality
 Shan [70] 2016 China Prospective 142 ELISA (commercial, not specified) 90‑day mortality
 Tsirigotis [71] 2016 Greece Prospective 105 ELISA (ViroGates) 28‑day and ICU mortality
 Zeng [72] 2016 China Prospective 126 ELISA (USCN Life Science) 28‑day mortality
Total number of patients = 3080
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Fig. 2 Forest plots of pooled mean differences in biomarker concentration (nonsurvivors − survivors). Effect estimates to the left of 0 indicate 
higher biomarker concentrations in survivors. Effect estimates to the right of 0 indicate higher biomarker concentrations in nonsurvivors. SD 
standard deviation, MD mean difference; setting of study: ED emergency department, ICU intensive care unit, MICU medical intensive care unit, SICU 
surgical intensive care unit, HW hospital ward
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but to a lesser degree than the other biomarkers. The 
pooled mean difference for sTREM-1 is 87 pg/ml (95% 
CI 2 to 171; p = 0.04) (Fig. 2).
Heterogeneity between studies was considered sig-
nificant for the analyses of sTREM-1 with an I2 of 93% 
(p < 0.01), so a random effects model was used for pool-
ing of the results.
ROC analyses were reported in 8 studies. The AUCs 
had varying values, from 0.444 to 0.856 (Table 2).
Three studies did not report sufficient data for the 
meta-analysis or details of ROC analyses [54, 55, 57].
Giamarellos-Bourboulis et  al. studied the kinetics 
of sTREM-1 in patients with sepsis due to ventilator-
associated pneumonia (VAP). On day 1, they found 
Table 2 ROC analyses for prediction of mortality according to baseline (< 24 h of admission) biomarker concentration
ICU intensive care unit, ROC receiver operating characteristic, AUC area under the curve, Sn sensitivity, Sp specificity, PPV positive predictive value, NPV negative 
predictive value, LR+ positive likelihood ratio, LR− negative likelihood ratio
Study Mortality follow‑up AUC (95% CI) Cutoff Sn Sp PPV NPV LR+ LR−
Angiopoietins 1 and 2
 Ang‑2/Ang‑1 ratio
  Fang [30] 28 days 0.845 (0.810 to 0.880) 1.94 80% 81% 78% 83% 3.98 0.31
 Ang‑1
  Ricciuto [36] 28 days 0.620 (0.500 to 0.760) – – – – – – –
  Lin [32] During hospital stay 0.743 (0.726 to 0.847) – – – – – – –
  Fang [30] 28 days 0.778 (0.732 to 0.824) – – – – – – –
 Ang‑2
  Lin [32] During hospital stay 0.632 (0.515 to 0.750) – – – – – – –
  Kranidioti [31] 28 days 0.703 (0.578 to 0.827) 9700 pg/ml 42% 82% 51% 76% 2.32 0.49
  van der Heijden [38] ICU mortality 0.790 3066 pg/ml 73% 71% 39% 91% 2.52 0.38
  Fang [30] 28 days 0.794 (0.750 to 0.837) – – – – – – –
  Palud [34] 28 days 0.960 (0.870 to 1.050) 26,780 pg/ml 100% 93% 83% 100% 14.29 0
HMGB1
 Karlsson [42] During hospital stay 0.570 (0.470 to 0.670) 6.5 ng/ml 39% 79% 40% 79% 1.87 0.77
 Gibot [40] 28 days 0.610 – – – – – – –
sRAGE
 Bopp [50] 28 days – 1569 pg/ml 85% 75% 73% 86% 3.38 0.21
 Brodska [51] 28 days 0.660 (0.492 to 0.827) 1804 pg/ml 63% 76% 53% 83% 2.64 0.49
sTREM‑1
 Bayram [60] not specified 0.444 255 pg/ml 50% 40% 50% 40% 0.83 1.25
 Suarez‑Santamaria [56] 28 days 0.598 (0.520 to 0.676) 55.7 pg/ml 68% 58% 31% 87% 1.62 0.55
 Charles [61] ICU mortality 0.640 (0.540 to 0.740) 954 pg/ml 55% 78% 49% 82% 2.48 0.58
 Ravetti [47] 28 days 0.640 (0.460 to 0.830) 750 pg/ml 56% 68% 60% 65% 1.75 0.65
 Ravetti [47] ICU mortality 0.690 (0.510 to 0.870) 750 pg/ml 56% 75% 60% 72% 2.24 0.59
 Gibot [53] 28 days 0.740 (0.680 to 0.800) 180 pg/ml 86% 70% 59% 91% 2.87 0.20
 Su [58] 28 days 0.748 (0.637 to 0.860) 0.499 63% 84% 81% 54% 4.01 0.43
 Brenner [62] 90 days 0.827 521 pg/ml 71% 86% 87% 79% 4.99 0.33
 Li [59] 28 days 0.856 (0.784 to 0.929) 252 pg/ml 86% 76% 71% 88% 3.53 0.19
suPAR
 Suberviola [66] During hospital stay 0.670 (0.570 to 0.770) 9.6 ng/ml 81% 46% 39% 85% 1.49 0.43
 Giamarellos‑Bourboulis [63] 28 days 0.708 (0.681 to 0.736) 12.0 ng/ml 62% 69% 36% 87% 1.99 0.55
 Khater [68] 30 days 0.720 (0.560 to 0.853) 6.3 ng/ml 79% 63% 76% 67% 2.11 0.33
 Donadello [67] ICU and 28 days 0.723 10.2 ng/ml 71% 65% 38% 88% 2.03 0.45
 Zeng [72] 28 days 0.765 (0.658 to 0.872) 12.0 ng/ml 87% 73% 66% 90% 3.17 0.18
 Shan [70] 90 days 0.780 (0.630 to 0.930) 310 pg/ml 69% 65% – – – –
 Tsirigotis [71] 28 days 0.787 7.6 ng/ml 82% 73% 63% 88% 3.04 0.25
 Liu [69] 28 days 0.788 (0.73 to 0.846) 10.8 ng/ml 85% 78% 39% 97% 3.79 0.19
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significantly higher levels of sTREM-1 in nonsurvivors 
compared to survivors.
Phua et  al. did not find sTREM-1 to be predictive of 
mortality in a cohort of patients with septic shock. Zhang 
et al. evaluated sepsis patients and while they showed that 
nonsurvivors had higher sTREM-1 concentrations than 
survivors on day 1, the difference was not significant.
suPAR
suPAR was determined in 10 of the 44 studies [63–72]. 
The sample size ranged from 49 to 1914 patients. The age 
of the patients was consistent, ranging from a mean or 
median of 59 years to 71 years.
We could include 6 of these studies in the meta-analy-
sis. Our results strongly indicate that suPAR is higher in 
nonsurvivors than in survivors. The pooled mean differ-
ence for suPAR is 5.2 ng/ml (95% CI 4.5 to 6.0; p < 0.01) 
(Fig. 2).
The heterogeneity between studies was not significant 
(I2 = 46%; p = 0.10), and the results were pooled using a 
fixed effects model.
Eight of the 10 studies contained data regarding ROC 
analyses. The AUC for suPAR for prediction of mortality 
ranged from 0.670 to 0.788 (Table 2).
One study [65] was not included in the meta-analysis 
and did not contain information regarding ROC analysis. 
Hoenigl et  al. studied suPAR concentration in patients 
with SIRS or sepsis. In their whole cohort, suPAR con-
centrations were significantly higher in nonsurvivors 
than in survivors. In the subgroup of patients with sep-
sis, they describe that patients with increasing suPAR 
concentrations within day 1 following admission to the 
emergency department had a higher mortality rate than 
those who had decreasing concentrations of suPAR.
Study quality
The overall results of quality assessment, as well as the 
quality of studies for each biomarker, are displayed in 
Fig. 3. No studies were excluded due to low quality.
We found selection bias to be a concern for more than 
half of the included studies. This was due to studies not 
following consecutive recruitment, no or partial defini-
tion of inclusion and exclusion criteria as well as time 
and/or place of recruitment.
Study attrition and risk of attrition bias was very low, as 
almost no patients were lost to follow-up across studies. 
The proportion of missing data was also low. The reasons 
for missing data were often missing blood samples when 
repeated measurements were made, or, for studies which 
assessed survival by phone at 90 days, missing informa-
tion on survival status.
The time and measurement of biomarkers was well 
described, with only 2 studies not reporting the sampling 
timeframe.
Mortality was well defined in 40 studies, but 4 studies 
did not report the follow-up period for mortality.
Confounding was another large source of bias. Only 14 
studies adequately recorded confounders (such as comor-
bidities) and controlled for confounding by restriction or 
adjustment for the assessment of their outcome. Nine 
studies partly accounted for confounding. The remaining 
21 studies were at high risk of bias due to no or insuffi-
cient recognition and control for confounding.
We found 4 studies susceptible to risk of bias due to 
inadequate statistical analysis or reporting of results. This 
was engendered by the partial reporting of primary out-
comes, insufficient data disclosure, or multiplicity issues 
due to the reporting of a large number of outcomes, 
which meant that results were likely to be spurious.
Discussion
The results of our meta-analysis show that of the 6 bio-
markers we evaluated, Ang-1, Ang-2, sRAGE and suPAR 
are the ones that most highly differ at onset of the disease 
between patients dying of sepsis and those who survive. 
sTREM-1 slightly differed between those two groups, 
but the evidence was less compelling. Our results do not 
show evidence that HMGB1 distinguishes nonsurvivors 
from survivors.
The results of ROC analyses further support the pre-
dictive value of Ang-1, Ang-2, and suPAR for mortality 
in sepsis patients. These biomarkers show superior AUC 
values, specificity and sensitivity than sRAGE, sTREM-1 
and HMGB1. Additionally, their AUC values are com-
parable to those of biomarkers currently clinically in 
use such as procalcitonin (PCT) [73, 74], or clinical 
scores such as the Sequential Organ Failure Assessment 
(SOFA) score [75]. Regarding negative and positive pre-
dictive values, in general, all six biomarkers have higher 
NPVs than PPVs. The PPV between biomarkers is similar, 
except HMGB1 for which it is lower. All biomarkers show 
high NPVs, except sTREM-1 which has a lower range of 
values.
Biomarkers are routinely used in day-to-day clinical 
practice. In the ICU, few biomarkers other than PCT 
have demonstrated reliability for the prediction of mor-
tality in sepsis patients, which has prompted the search 
for new biomarkers [4, 5]. Some of the six biomarkers 
we evaluated have been analyzed in systematic reviews 
of studies with varying cohorts of ICU patients. Backes 
et al. [14] evaluated the diagnostic and prognostic value 
of suPAR in a narrative review of studies of patients with 
systemic inflammation, bacteremia, or sepsis. They con-
clude that suPAR shows encouraging prognostic value, 
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with higher levels being associated with increased mor-
tality. More recently, Ni et al. [17] performed a systematic 
review with meta-analysis about the diagnostic and prog-
nostic value of suPAR, focusing on patients with bacte-
rial infection with or without sepsis. Their results show 
that high suPAR is associated with an elevated risk of 
mortality, with a pooled risk ratio of 3.37 (95% CI 2.60 to 
4.38), and an AUC of 0.77 for the prediction of mortality, 
with pooled sensitivity and specificity of 70% and 72%. 
Regarding sTREM-1, in another recent systematic review 
with meta-analysis of patients with infection, Su et  al. 
[16] concluded that it only had moderate prognostic 
value and is not significant for the prediction of mortal-
ity. They reported a pooled risk ratio (RR) of death with 
elevated sTREM-1 of 2.54 (95% CI 1.77 to 3.65), and an 
AUC of 0.76 for the prediction of mortality, with pooled 
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sensitivity and specificity of 75% and 66%. Xing et al. [15] 
reviewed biomarkers of endothelial activation in sepsis, 
including Ang-1 and Ang-2, and narratively summarized 
studies which are also included in our review. The recent 
meta-analysis by Jabaudon et  al. [76] supports sRAGE 
as a predictor of poor outcome in ARDS patients. How-
ever, these systematic reviews all had different inclusion 
criteria and combined cohorts of patients with various 
diseases.
A strength of our study is the evaluation of multiple 
biomarkers which intervene in different aspects of sepsis 
pathophysiology. Additionally, the majority of included 
studies are prospective, and we selected only studies 
with cohorts or subgroups of patients with a diagnosis 
of sepsis according to well defined criteria, not mixed 
with other ICU patients. Many other biomarkers, which 
are not yet routinely used clinically emerged in addition 
to the six biomarkers assessed in this systematic review. 
However, the measurement methods are complex or 
expensive, which could slow their future implementation 
in the clinic, while others are more useful for the diagno-
sis than for the prognosis of sepsis. This is the reason why 
we focused on the six biomarkers only. To eliminate any 
risk of selective reporting, the list of the six biomarkers 
chosen for this systematic review was determined before 
the start of the study and published in the PROSPERO 
protocol (CRD42018081226).
Our study has some limitations. While we had strict 
inclusion criteria regarding the definition of sepsis, there 
is still inevitable variability due to the heterogeneous 
nature of sepsis and the various study populations from 
different centers. Furthermore, resulting from the lack 
of standardization, a variety of assays were used for the 
measuring of the biomarkers. However, even in presence 
of this heterogeneity the results are consistent across 
studies which suggests a good robustness of the biomark-
ers, especially suPAR, Ang-1 and Ang-2.
Mortality was not assessed at the same time point, 
but the majority of studies assessed mortality at 28 days 
or during hospital or ICU stay. For the meta-analysis, 
we used means with SDs of biomarker concentrations 
to pool the results. As we did not have access to the 
original data, we had to estimate the mean and SD of 
biomarker concentrations when they were reported 
as median and range or IQR. These estimations were 
performed using the methods by Wan et  al. [22], in 
duplicate according to the methods by Luo et al. [23] to 
confirm their accuracy and to reduce bias. Both these 
methods have shown good reliability for these estima-
tions even in presence of deviation from the normal 
distribution [24]. No difference was found between the 
estimations using the two methods. In addition, even if 
bias for the estimation of the mean and SD was present, 
the bias would be canceled out for the estimation of 
the mean difference between nonsurvivors and survi-
vors as it would be found in both groups [77]. A lot of 
studies did not contain data on biomarker concentra-
tions at baseline and could not be included in the meta-
analysis. There is a particularly low number of studies 
for Ang-1 and sRAGE. Statistical pooling of the results 
of ROC analyses to provide a summary ROC curve for 
each biomarker was not feasible due to the low number 
of studies, and more importantly because of the lack of 
standardization of biomarker measurement methods, 
which makes the different cutoff points not directly 
comparable. The results of all ROC analyses reported 
within studies were therefore narratively summarized.
Some studies performed repeated measurements to 
assess the dynamics of biomarker concentration over 
time. Biomarkers which do not clearly distinguish 
between survivors and nonsurvivors at onset of sepsis 
(HMGB1 and sTREM-1) could still provide important 
prognostic information when assessed at a further time 
point. But as biomarker concentrations over time are less 
practical to use, and subject to additional variability due 
to factors such as fluid resuscitation, this was not a focus 
of our review.
As mentioned previously, the AUC values of the bio-
markers assessed, which performed best (Ang-1, Ang-2 
and suPAR) are comparable to AUCs reported in the lit-
erature for clinical scores or other biomarkers currently 
used in clinical settings. Within this systematic review, a 
few of the included studies also reported AUCs for clini-
cal scores. In 3 studies for angiopoietins, the AUCs of 
Ang-1 and Ang-2 were comparable to those of the Mor-
tality in Emergency Department Sepsis (MEDS), SOFA 
and Acute Physiology and Chronic Health Evaluation 
(APACHE) II scores for predicting mortality [30, 32, 
36]. In 5 studies for sTREM-1, one study showed a simi-
lar AUC between sTREM-1 and APACHE-II, and in the 
other 4 studies, sTREM-1 had a lower AUC than either 
the Simplified Acute Physiology Score (SAPS) II, SOFA 
and/or APACHE-II scores [56, 58–61]. suPAR had worse 
AUC values than APACHE-II or SOFA for the predic-
tion of mortality in 4 studies, was comparable to SOFA 
score but worse than APACHE-II in 2 studies, and bet-
ter than APACHE-II in one study [63, 66–69, 71, 72]. 
However, as the prognostic value of clinical scores was 
not a predefined outcome nor an inclusion or exclusion 
criteria of our systematic review, this comparison was 
not addressed in a systematic fashion and therefore may 
be biased. Comparing the value of the six biomarkers 
to clinical scores (or to other well-known biomarkers), 
either narratively or quantitatively, deserves to be evalu-
ated as main outcome in future studies.
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Additionally, as sepsis is a very heterogeneous condi-
tion, it is unlikely that a single biomarker will accurately 
predict outcome in all cases. Combining multiple bio-
markers as a panel might better reflect the individual 
disease process of each patient, and thus provide added 
value compared to single biomarkers [12, 78]. But it is still 
necessary to determine which biomarkers to include in 
such a panel, and the biomarkers included in this system-
atic review which performed best (Ang-1, Ang-2, suPAR) 
are attractive candidates. Further studies evaluating the 
prognostic value of combinations of multiple biomarkers 
or biomarkers with clinical scores are encouraged.
Conclusions
In summary, we evaluated the prognostic value of six 
different biomarkers at onset of sepsis, by assessing the 
difference in biomarker concentration between nonsurvi-
vors and survivors, and by reporting their performance 
for predicting mortality. Of the biomarkers we evaluated, 
Ang-1, Ang-2, and suPAR provide the most beneficial 
prognostic information about mortality in adult patients 
with sepsis. The further development of standardized 
assays and the assessment of their role when included in 
panels with other biomarkers may be recommended.
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